The Genome Institute at Washington University and the Division of Oncology from the Department of Medicine are pleased to announce the inaugural meeting of a new, multidisciplinary Genomics Tumor Board, an educational and interactive forum for cancer case presentation, sequencing, analysis and therapeutic prediction.

The conference will be held the first Tuesday of each month at 4 pm in the Farrell Conference Room on the 3rd Floor of the Center for Advanced Medicine. The first conference will be held on Tuesday, October 1. All interested faculty and trainees are encouraged to attend.

The first three conferences will provide a didactic overview of clinical cancer sequencing and a survey of the genomic discovery and analysis capabilities available at both The Genome Institute (TGI) and Genomics and Pathology Services (GPS@WUSTL). Starting with the 4th conference on January 7, medical and surgical oncologists will be invited to present clinical cases for discussion at the meeting. A consultant group of junior faculty will be available to work with oncologists interested in case presentation. An advisory committee made up of genomicists, oncologists and pathologists will determine whether clinical sequencing is appropriate for each case and which platform(s) would be most informative. They will then arrange for the sequencing and analysis to be performed, with all funding provided by The Genome Institute and Division of Oncology. We anticipate that approximately one case will be selected for sequencing and analysis each month. The sequencing report, and how it affected clinical decision-making, will be reported at subsequent conferences for all cases going forward. Cases where genomic studies are likely to influence decision-making, clarify diagnosis, and/or lead to publishable studies or grant funding will receive the highest priority for sequencing.

The itinerary for the October 1st Genomics Tumor Board is as follows:

1. Richard K. Wilson, Ph.D., Professor of Genetics, Director of The Genome Institute: Overview of next-generation sequencing and analysis for cancer genomics

2. Robert Fulton, Research Instructor of Genetics, Group Leader for Sequence Improvement at The Genome Institute: Overview of current platforms for sequencing—including the performance specifications, cost, data yield, strengths and limitations of each platform

3. Christopher A. Maher, Ph.D., Assistant Professor of Medicine and Genetics, Assistant Director of The Genome Institute: Overview of the analytical pipeline for sequencing data and what each type of data (whole genome, exome, transcriptome) can deliver to the therapeutic analysis

4. John S. Welch, M.D., Ph.D., Assistant Professor of Medicine: Presentation of an atypical case of acute promyelocytic leukemia

For further information, please contact Dr. Lukas Wartman at Lwartman@dom.wustl.edu.